TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 75 years of age~* Written informed consent including authorization to release health information~* Focal upper limb spasticity (ULS) after a stroke (as defined by WHO criteria) or traumatic brain injury (TBI), last stroke or TBI \> 24 weeks prior to Screening~* ULS with the primary aggregate posture~* Moderate to severe ULS with a MAS score ≥ 2 at the elbow, wrist, and finger flexors~* Moderate to severe functional disability (Disability Assessment Score \[DAS\] score ≥2) on the principal target of treatment~* Has sufficient cognitive and communication ability to be able to give informed consent~Exclusion Criteria:~* Upper limb spasticity attributable to an etiology other than stroke or TBI.~* Bilateral upper limb paresis or quadriplegia.~* Initiated in physiotherapy of the upper extremities ≤ 30 days prior to Screening or planned to start physiotherapy of the upper extremities during the course of the study.~* Previous or planned treatment of the spastic upper limb with phenol, alcohol injection, or surgery~* Profound muscular atrophy or fixed contracture leading to marked limitation on range of motion~* Prior treatment with intrathecal baclofen~* Any neuromuscular neurologic conditions (amyotrophic lateral sclerosis, Lambert- Eaton, myasthenia gravis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DAXI 250 U (Type: EXPERIMENTAL): DAXI for injection for the treatment of Upper Limb Spasticity (ULS) in Adults with 250 U dose
- DAXI 375 U (Type: EXPERIMENTAL): DAXI for injection for the treatment of Upper Limb Spasticity (ULS) in Adults with 375 U
- DAXI 500 U (Type: EXPERIMENTAL): DAXI for injection for the treatment of Upper Limb Spasticity (ULS) in Adults with 500 U
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 18-70 years~* ischemic chest pain for \>30 min~* admitted to hospital \<24 h after the onset of chest pain~* electrocardiography showed ST segment elevation \>1 mm in two consecutive leads in the limb leads or \>2 mm in the precordial leads~* they could be enrolled in the study \<72 h after successful revascularization~Exclusion Criteria:~* cardiogenic shock (defined as systolic blood pressure \<90 mmHg requiring intravenous pressors or intra-aortic balloon counterpulsation)~* life-threatening arrhythmia~* impossible conditions for cardiac catheterization~* advanced renal or hepatic dysfunction~* history of previous coronary artery bypass graft~* history of hematologic disease~* history of malignancy~* major bleeding requiring blood transfusion~* stroke or transient ischemic attack in the previous 6 months~* structural abnormalities of the central nervous system (brain tumor, aneurysm, history of surgery)~* traumatic injury after myocardial infarction~* use of corticosteroids or antibiotics during the previous month~* major surgical procedure in the previous 3 months~* cardiopulmonary resuscitation for \>10 min within the previous 2 weeks~* positive skin test for penicillin~* positive result for viral markers (human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and Venereal Disease Research Laboratory (VDRL) test)~* pregnancy, possible candidate for pregnancy or breastfeeding females~* drug abusers~* inappropriate patients to participate in the study according to the chief investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stem cell treatment group (Type: ACTIVE_COMPARATOR): None
- Control group (Type: PLACEBO_COMPARATOR): All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria include:~1. Diagnosis type I Diabetes Mellitus for at least 12 months~2. Receiving treatment with multiple daily insulin injections or insulin pump therapy for at least 12 months~3. Fasting C-peptide concentration ≤8.5% (≤69 mmol/mol) at screening~4. BMI 18.5-35.0 kg/m2~Exclusion Criteria include:~1. known or suspected hypersensitivity to Investigational Medicinal Products~2. clinically significant concomitant disease or abnormal lab values~3. supine systolic BP outside range 95-140 mmHg and/or diastolic BP greater than 90 mmHg

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- AT247 (Type: EXPERIMENTAL): Single subcutaneous injection 0.3 U/Kg
- NovoRapid (Type: ACTIVE_COMPARATOR): Single subcutaneous injection 0.3 U/Kg
- Fiasp (Type: ACTIVE_COMPARATOR): Single subcutaneous injection 0.3 U/Kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Acne Treatment in Children Ages 9 to 11

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and non-pregnant, non-nursing females, 9 to 11 years, with facial pediatric acne vulgaris~* Minimum of 20 non-inflammatory lesions (open and closed comedones)~* Minimum of 30 total facial lesions (sum of inflammatory and non-inflammatory)~* Must have at least a rating of grade 3 on the Investigator Global Assessment Scale for acne severity (IGA #1) at baseline~Exclusion Criteria:~* Known sensitivity to any of the ingredients in the study medication;~* Any nodulocystic acne lesions~* Use of acne devices or systemic therapy with antibiotics within two months prior to start and throughout the duration of the study~* Use of systemic therapy with retinoids within four months prior to study start and throughout the duration of the study~* Topical use of topical retinoids within two weeks prior to study start and throughout the duration of the study~* Topical use of antibiotics, steroids and/or other non-retinoid topical acne products within two weeks prior to study start and throughout the duration of the study~* Use of an experimental drug or device within 60 days prior to study start;~* Use of hormonal therapy within 3 months prior to study start~* History of evidence of other skin conditions or diseases that may require concurrent therapy or may interfere with the evaluation of the study medication~* Any significant medical conditions that could confound the interpretation of the study~* History of/or current facial skin cancer~* Inability to refrain from use of all facial products other than those supplied by the study, while participating in the study~* No use of tanning booths, sun lamps, etc.~* Subject is a family member of the employee or the investigator

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Retin-A Micro (Type: EXPERIMENTAL): Retin-A Micro 0.04% facial acne treatment used once daily
- Vehicle Control (Type: PLACEBO_COMPARATOR): Color matched facial gel vehicle control used once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of LEDs on Memory in TBI Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, Ages 18-65~* sustained a mild traumatic brain injury(mTBI) at least 6 months ago~* mTBI is defined as \< 30 minutes loss of consciousness and \<30 minutes, post trauma amnesia~* since the injury patient continues having problems with memory and thinking ability~Exclusion Criteria:~* Younger than 18 or older than 65~* mTBI occured less than 6 months ago~* moderate to severe Traumatic Brain Injury (TBI)~* non-closed head injury~* presence of craniotomy, craniectomy, or ventriculoperitoneal shunt~* Non-English speaking subjects - Neuropsychological Tests only in English~* Neuropsychological Screening Test Scores not at least 2 SD below norm on one of the neuropsychological tests or not 1 SD below norm on at least two of the tests administered during screening)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transcranial LED Treatment (Type: EXPERIMENTAL): All study subjects received treatment during 6-Week period (3x per week) for a total of 18 Transcranial LED Treatments using the MedX Health Phototherapy (light). Each session was 30 minutes in duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged greater than or equal to 18 years and less than or equal to 70 years.~2. BMI \>27.5 (based on kg/m2)~4. Not taking acid suppressant PPI and H2 receptor blockers 5. Not taking antacids or alginate preparations, except those administered as part of study procedure.~Exclusion Criteria:~1. Those with gastrointestinal symptoms indicative of GERD, gastric carcinoma, previous or current peptic ulcer disease.~2. Those with a history of upper GI surgery prior to this.~3. Those with haematological disorders, bleeding tendency, recurrent nose bleeds or treatment with anti-coagulants).~4. Those who had any previous history of allergy or known intolerance to any of the study drugs or the following formulation constituents: Gaviscon® liquid: sodium alginate, sodium bicarbonate and calcium carbonate~5. Those with physical, neurological or psychiatric conditions preventing repeated visits to hospital or compliance with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Alginate-antacid group (Type: EXPERIMENTAL): Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus alginate-antacid.
- Non antacid alginate group (Type: EXPERIMENTAL): Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus antacid alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* A clinical diagnosis of hereditary angioedema (HAE) Type 1 or Type 2, defined as having a C1-INH functional level and a C4 level below the lower limit of the normal (LLN) reference range, as assessed during the Screening period.~* Access to and ability to use one or more acute medications approved by the relevant competent authority for the treatment of acute attacks of HAE~* Subjects must be medically appropriate for on-demand treatment as the sole medicinal management for their HAE during the study.~* Subjects must have a specified number of expert-confirmed attacks during the run-in period of 56 days from the Screening visit.~* Acceptable effective contraception~* Written informed consent~Key Exclusion Criteria:~* Pregnancy or breast-feeding~* Any clinically significant medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study~* Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study~* Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology~* Use of C1-INH within 14 days or use of androgens or tranexamic acid within 28 days prior to the Screening visit for prophylaxis of HAE attacks, or initiation of these drugs during the study~* Current participation in any other investigational drug study or received another investigational drug within 30 days of the Screening visit~* Prior enrollment in a BCX7353 study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BCX7353 110mg once daily (Type: EXPERIMENTAL): BCX7353 capsules administered orally once daily
- BCX7353 150mg once daily (Type: EXPERIMENTAL): BCX7353 capsules administered orally once daily
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo oral capsules administered orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who successfully completed Study A3921030~Exclusion Criteria:~* Subjects who are on the waiting list for a second kidney transplant or any non-renal organ transplants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm 1 (Type: ACTIVE_COMPARATOR): Treatment Arm 1 will also receive standard of care medications
- Treatment Arm 2 (Type: EXPERIMENTAL): Treatment Arm 2 will also receive standard of care medications
- Treatment Arm 3 (Type: EXPERIMENTAL): Treatment Arm 3 will also receive standard of care medications

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immune Responses to the Flu Shot During Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* less than 29 weeks pregnant~* ages 18-42~* planning to deliver at The Ohio State University Wexner Medical Center~Exclusion Criteria:~* prior serious adverse reaction to seasonal influenza vaccine

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Study Arms:
- Flu Shot (Type: None): pregnant women receive a seasonal influenza virus vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Healthy male or female Japanese and Caucasian volunteers ≥18 and ≤55 years of age at the screening visit.~* Japanese subjects must:~  1. Be first generation Japanese, defined as born in Japan and both biologic parents are ethnic Japanese~ 2. Have maintained a Japanese lifestyle that has not significantly changed since leaving Japan, including having access to Japanese food and adhering to a Japanese diet.~* Caucasian subjects must be Caucasian of European or Latin American descent~* Modest elevations in LDL-C (≥100 mg/dL, but \<160 mg/dL)~Key Exclusion Criteria:~* Significant concomitant illness~* Known allergy or sensitivity to monoclonal antibodies (mAbs)~* Previous exposure to anti-ANGPTL3 antibody~* Body mass index (BMI) \>35 kg/m2 at the screening visit~Note: Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Evinacumab SC or placebo SC
- Cohort 2 (Type: EXPERIMENTAL): Low dose regimen: evinacumab IV or placebo IV
- Cohort 3 (Type: EXPERIMENTAL): High dose regimen: evinacumab IV or placebo IV
- Cohort 4 (Type: EXPERIMENTAL): Evinacumab or placebo SC every week (QW) x 8 doses
- Cohort 5 (Type: EXPERIMENTAL): Evinacumab or placebo SC x 1 dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic spontaneous urticaria refractory to H1 antihistamines at Baseline~Exclusion Criteria:~* Clearly defined underlying etiology for chronic urticarias other than CIU (main manifestation being physical urticaria). This includes the following urticarias: Acute, solar, cholinergic, heat, cold, aquagenic, delayed pressure or contact, as well as the following diseases as these diseases may have symptoms of urticaria or angioedema: Urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, lymphoma, leukemia, or generalized cancer.~* Previous treatment with omalizumab.~* A history or presence of atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or other skin disease associated with itch.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IGE025 (Type: EXPERIMENTAL): Patients will receive omalizumab administered subcutaneously every 4 weeks at the study center.
- Placebo to IGE025 (Type: PLACEBO_COMPARATOR): Placebo administered subcutaneously every 4 weeks at the study center.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of CDB-2914 for Emergency Contraception

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or more~* Menstruating women with regular menstrual cycle between 24 and 35 days and intra-individual variations less than or equal to 5 days~* Request emergency contraception between 48 hours and 120 hours after unprotected intercourse as defined by lack of contraceptive use, or condom breakage (including condoms lubricated with spermicide) or other barrier contraceptive method failure~* No current use of hormonal contraception and having had at least one complete menstrual cycle (2 menses) since having stopped hormonal contraception~* For women with a recent history of Depo Provera use, the most recent injection must have been at least 9 months before study entry and followed by at least one complete menstrual cycle (2 menses)~* Willing to not use hormonal methods of contraception until study completion~* At least one complete menstrual cycle (2 menses) post delivery, miscarriage or abortion~* Able to provide informed consent in English~* Give voluntary, written informed consent, and agree to observe all study requirements (the subject needs to be available for follow-up over the next 6 weeks)~* Willing to abstain from further acts of unprotected intercourse during participation in the study and until pregnancy status has been ascertained~Exclusion Criteria:~* One or more acts of one unprotected intercourse more than 120 hours before requesting emergency contraception in the current cycle~* All acts of unprotected intercourse (in the current cycle) within 48 hours of presentation~* Currently pregnant as confirmed by positive HSUP test performed at screening~* Currently breast-feeding~* Current use of hormonal contraception~* Use of hormonal emergency contraception since last menstrual period~* Current use of IUD~* Tubal ligation~* Partner with a vasectomy~* Unsure about the date of the last menstrual period~* Severe asthma insufficiently controlled by oral glucocorticoid~* Currently enrolled in any other trial of an investigational medicine

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDB-2914 (Type: EXPERIMENTAL): A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CBD-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Intercourse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete